RxDoctor Payments Data

Jordan Dunitz, MD

Pulmonary Disease · Minneapolis, MNNPI 1760413124

Payments from drug & device makers

What this record shows

This record is dominated by education: $96 of the $112 with a category attached, or 85.9%. 3 manufacturers reported payments, led by Insmed, Inc. at 57.8% of the total. Reporting peaked in 2021 at $80 and has fallen 79.7% since, to $16 in 2022. That places this record below the midpoint for pulmonary disease clinicians in MN, where the typical reported total is $128.

$112in general payments, 2019–2025

Across 6 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$65
  • Vertex$32
  • Fisher & Paykel Healthcare Inc$16
$147,205in research payments, 2019–2025

Across 9 payments — averaging $16,356 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$91K
  • Hill-rom Company, Inc$56K

What the payments were for

  • Food & beverage$1614%
  • Education$9686%

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Insmed, Inc.4$65
Vertex1$32
Fisher & Paykel Healthcare Inc1$16

How this compares

$112 in reported general payments places this provider in the 45th percentile of 261 pulmonary disease providers in Minnesota.

See all pulmonary disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$55,497
Medicare patients
105
Services billed
648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft123$3,264,663
CreonLipase/Protease/Amylase58$307,835
CaystonAztreonam Lysine21$248,356
PancreazeLipase/Protease/Amylase13$36,090
EliquisApixaban46$31,394
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium23$21,758
Fluticasone-SalmeterolFluticasone Propion/Salmeterol80$16,408
Aztreonam16$13,756
MicafunginMicafungin Sodium20$13,062
Voriconazole18$11,806
Tacrolimus88$7,364
Azithromycin186$5,519
AmitizaLubiprostone13$5,281
Meropenem16$3,914
Ursodiol14$3,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
VertexTrikafta$32$3,264,663123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 261 pulmonary disease providers in Minnesota.

Other pulmonary disease in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →